首页 > 最新文献

European Cardiology Review最新文献

英文 中文
Management of Coronary Artery Spasm. 冠状动脉痉挛的治疗。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.47
Gaetano Antonio Lanza, Hiroaki Shimokawa

Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy.

钙通道阻滞剂(CCBs)是治疗冠状动脉痉挛(CAS)的一线药物。当CCB治疗不能很好地控制cas相关心绞痛症状时，可添加长效硝酸盐或(如有)尼可地尔作为二线药物。在标准治疗难治性CAS的情况下，已经提出了几种其他替代药物和干预措施，包括rho激酶抑制剂法舒地尔、抗肾上腺素能药物、神经疗法和经皮冠状动脉介入治疗。对于由cas相关性快速心律失常，甚至慢速心律失常引起的晕厥或心脏骤停患者，应根据复发风险和血管扩张剂治疗效果，分别考虑植入ICD或起搏器。
{"title":"Management of Coronary Artery Spasm.","authors":"Gaetano Antonio Lanza,&nbsp;Hiroaki Shimokawa","doi":"10.15420/ecr.2022.47","DOIUrl":"https://doi.org/10.15420/ecr.2022.47","url":null,"abstract":"<p><p>Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e38"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/58/ecr-18-e38.PMC10345953.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
The Relationship between Neutrophil to Lymphocyte Ratio with Rehospitalisation and Mortality in Patients with Acute Coronary Syndrome. 急性冠脉综合征患者中性粒细胞与淋巴细胞比值与再住院及死亡率的关系。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO12
J Lesmana, A Lefi
{"title":"The Relationship between Neutrophil to Lymphocyte Ratio with Rehospitalisation and Mortality in Patients with Acute Coronary Syndrome.","authors":"J Lesmana,&nbsp;A Lefi","doi":"10.15420/ecr.2023.18.PO12","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO12","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e29"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/37/ecr-18-e29.PMC10316359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10160561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Mortality Predictors of Patients Evaluated with Pharmacologic Cardiac Stress SPECT (PS-SPECT) for Suspicion of Chronic Coronary Syndrome. 用药理学心脏应激SPECT (PS-SPECT)评估疑似慢性冠脉综合征患者的长期死亡率预测因素。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO16
Nuria Mallofré
{"title":"Long-term Mortality Predictors of Patients Evaluated with Pharmacologic Cardiac Stress SPECT (PS-SPECT) for Suspicion of Chronic Coronary Syndrome.","authors":"Nuria Mallofré","doi":"10.15420/ecr.2023.18.PO16","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO16","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e33"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/49/ecr-18-e33.PMC10316350.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Vitamin D in Experimental Pulmonary Arterial Hypertension in Rats: Possible Role of eNOS-mediated Signalling Pathways. 维生素D在实验性肺动脉高压大鼠中的作用:enos介导的信号通路的可能作用。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO11
Harlokesh Narayan Yadav, Sadia Shah
{"title":"Effect of Vitamin D in Experimental Pulmonary Arterial Hypertension in Rats: Possible Role of eNOS-mediated Signalling Pathways.","authors":"Harlokesh Narayan Yadav,&nbsp;Sadia Shah","doi":"10.15420/ecr.2023.18.PO11","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO11","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e28"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/d3/ecr-18-e28.PMC10316370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HDL Mimetics Enhances Mitochondrial Function via Stimulation of PGC1-α. HDL模拟物通过刺激PGC1-α增强线粒体功能。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO10
Hang Zhang, Tomohiro Komatsu, Shihoko Nakashima, Satomi Abe, Emi Kawachi, Satoshi Imaizumi, Keijiro Saku, Yoshinari Uehara
{"title":"HDL Mimetics Enhances Mitochondrial Function via Stimulation of PGC1-α.","authors":"Hang Zhang,&nbsp;Tomohiro Komatsu,&nbsp;Shihoko Nakashima,&nbsp;Satomi Abe,&nbsp;Emi Kawachi,&nbsp;Satoshi Imaizumi,&nbsp;Keijiro Saku,&nbsp;Yoshinari Uehara","doi":"10.15420/ecr.2023.18.PO10","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO10","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e27"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/c4/ecr-18-e27.PMC10316335.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic? 口头报告奖得主:经皮冠状动脉介入治疗后糖尿病患者LDL-C降低:与非糖尿病患者有区别吗?
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO2
N Mallofré, G Torres, C Roca, P Rojas, M Sutil, N Casanovas, M Lloreda, F Castaldo, E Bosch, A Martínez-Rubio
{"title":"Oral Presentation Award Winner: LDL-C Reduction in Diabetic Patients after Percutaneous Coronary Intervention: Is There any Difference with Non-diabetic?","authors":"N Mallofré,&nbsp;G Torres,&nbsp;C Roca,&nbsp;P Rojas,&nbsp;M Sutil,&nbsp;N Casanovas,&nbsp;M Lloreda,&nbsp;F Castaldo,&nbsp;E Bosch,&nbsp;A Martínez-Rubio","doi":"10.15420/ecr.2023.18.PO2","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO2","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e19"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/2f/ecr-18-e19.PMC10316379.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification. 生物标志物在动脉粥样硬化性心血管疾病风险分层中的作用的现状和未来展望
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2022.57
Bruna Gigante
© The Author(s) 2023. Published by Radcliffe Group Ltd. www.ECRjournal.com Atherosclerotic cardiovascular diseases (ASCVD) remain the leading cause of death in Europe, with more than 4 million deaths in 2017.1 Ischaemic heart disease and stroke account for 82% of disability-adjusted life years (DALYs) in European Society of Cardiology member countries, even though ASCVD incidence has declined during the past 27 years.1
{"title":"Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification.","authors":"Bruna Gigante","doi":"10.15420/ecr.2022.57","DOIUrl":"https://doi.org/10.15420/ecr.2022.57","url":null,"abstract":"© The Author(s) 2023. Published by Radcliffe Group Ltd. www.ECRjournal.com Atherosclerotic cardiovascular diseases (ASCVD) remain the leading cause of death in Europe, with more than 4 million deaths in 2017.1 Ischaemic heart disease and stroke account for 82% of disability-adjusted life years (DALYs) in European Society of Cardiology member countries, even though ASCVD incidence has declined during the past 27 years.1","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e13"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/d3/ecr-18-e13.PMC10316363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9793293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Heart Failure-Exacerbating Medications among Heart Failure Patients in a Tertiary Referral Centre in Malaysia. 在马来西亚三级转诊中心心力衰竭患者中使用心力衰竭加重药物。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO20
Yii Ching Wong
{"title":"Use of Heart Failure-Exacerbating Medications among Heart Failure Patients in a Tertiary Referral Centre in Malaysia.","authors":"Yii Ching Wong","doi":"10.15420/ecr.2023.18.PO20","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO20","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e37"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/e1/ecr-18-e37.PMC10316340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study. Evolocumab在中欧和东欧的LDL-C水平比指南中推荐的高得多的患者中开始使用:观察性HEYMANS研究的结果。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO19
V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray
{"title":"Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.","authors":"V Blaha,&nbsp;R Margoczy,&nbsp;I Petrov,&nbsp;A Postadzhiyan,&nbsp;K Raslova,&nbsp;H Rosolova,&nbsp;I Bridges,&nbsp;N N Dhalwani,&nbsp;M Zachlederova,&nbsp;K K Ray","doi":"10.15420/ecr.2023.18.PO19","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO19","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e36"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Difficulties in Monitoring Antithrombotic Therapy in Patients with Atrial Fibrillation and Post-traumatic Hepatic and Splenic Visceral Haematomas. 心房颤动和创伤后肝、脾脏器血肿患者抗血栓治疗监测的困难。
IF 3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
European Cardiology Review
Pub Date : 2023-01-01 DOI: 10.15420/ecr.2023.18.PO14
Maria Cristina Beznă, Suzana Dănoiu, Marinela Beznă, Iulia-Andreea Voișneanu, Amelia Genunche-Dumitrescu, Larisa Săndulescu
{"title":"Difficulties in Monitoring Antithrombotic Therapy in Patients with Atrial Fibrillation and Post-traumatic Hepatic and Splenic Visceral Haematomas.","authors":"Maria Cristina Beznă,&nbsp;Suzana Dănoiu,&nbsp;Marinela Beznă,&nbsp;Iulia-Andreea Voișneanu,&nbsp;Amelia Genunche-Dumitrescu,&nbsp;Larisa Săndulescu","doi":"10.15420/ecr.2023.18.PO14","DOIUrl":"https://doi.org/10.15420/ecr.2023.18.PO14","url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e31"},"PeriodicalIF":3.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/69/ecr-18-e31.PMC10316343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
European Cardiology Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1